Healthcare Sales & Marketing Network News: AP23573

Searching News Database: AP23573

HSMN NewsFeed - 1 Aug 2007
Deforolimus Approved as Nonproprietary Name for AP23573 - ARIAD's Novel mTOR Inhibitor
Biopharmaceuticals Oncology

HSMN NewsFeed - 12 Jul 2007
ARIAD and Merck & Co., Inc. Announce Global Collaboration to Jointly Develop and Commercialize AP23573 - ARIAD's Novel mTOR Inhibitor - for Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 13 Jun 2007
ARIAD Announces Appointment of Senior Oncology Executive to Leadership Team
Biopharmaceuticals Personnel

HSMN NewsFeed - 3 Jun 2007
ARIAD Presents Additional Efficacy Data on AP23573, Novel mTOR Inhibitor, in Phase 2 Advanced Sarcoma Trial
Biopharmaceuticals Oncology

HSMN NewsFeed - 14 Apr 2007
ARIAD files claim against Amgen and Wyeth Alleging Infringement of NF-(kappa)B Patent by Enbrel(R) and Kineret(R)
Biopharmaceuticals Litigation

HSMN NewsFeed - 12 Feb 2007
ARIAD Grants Second Commercial License to Its Patented ARGENT(TM) Cell-Signaling Regulation Technology for Development of New Cancer Therapies
Biopharmaceuticals Oncology Licensing

HSMN NewsFeed - 2 Nov 2006
ARIAD Presents Expanded Efficacy Data On AP23573, Novel mTOR Inhibitor, In Phase 2 Advanced Sarcoma Cancer Trial
Biopharmaceuticals Oncology

HSMN NewsFeed - 11 Oct 2006
ARIAD Grants Commercial License to Its Patented ARGENT(TM) Cell-Signaling Regulation Technology for Development of New Cancer Therapies
Biopharmaceuticals Licensing

Return to NewsFeed

Additional items found! 18

Members: click here for search results from The HSMN Archive (password required)

Members Archive contains 18 additional stories matching:
AP23573
(Password required)

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.

FindReps - available on the Apple App Store for iPhone and iPad.